Patent US5972704A successfully refreshed from Google Patents.
US5972704A
Expired / Lapsed
US
⏱️ 0.0 years remaining
HIV nef targeted ribozymes
Assignee: Sirna Therapeutics Inc
•
Filing: 1997-08-13
•
Granted: 1999-10-26
•
Expires: 2017-08-13
Abstract
Abstract An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
Inventors
- 👤 Kenneth G. Draper
- 👤 Bharat Chowrira
- 👤 James McSwiggen
- 👤 Dan T. Stinchcomb
- 👤 James D. Thompson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 07:57
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C12N15/1132; C07; C07K; C07K14/00; C07K14/005; C12N15/63; C12N15/79; C12N15/85; C12N15/86; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/702; C12Q1/703; A; A61; A61K; A61K38/00; C12N2310/00; C12N2310/10; C12N2310/12; C12N2310/121; C12N2310/122; C12N2310/123; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/32; C12N2310/321; C12N2310/322; C12N2310/35; C12N2310/352; C12N2310/3521; C12N2310/353; C12N2310/3531; C12N2310/3533; C12N2310/3535; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16022
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
18 words
An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by the nef gene of human immunodeficiency virus.
Claim 2
Dependent Claim
18 words
An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by the nef gene of human immunodeficiency virus.
Claim 3
Dependent Claim
19 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hammerhead motif.
Claim 4
Dependent Claim
19 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hairpin motif.
Claim 5
Dependent Claim
33 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a group I intron, group II intron, hepatitis delta virus ribozyme or RNase P M1 RNA motif.
Claim 6
Dependent Claim
30 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a substrate binding site having between 12 and 100 nucleotides complementary to said nef RNA.
Claim 7
Dependent Claim
30 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a substrate binding site having between 14 and 24 nucleotides complementary to said nef RNA.
Claim 8
Dependent Claim
30 words
An expression vector comprising nucleic acid sequence encoding one or more enzymatic nucleic acid molecule of claim 1 in a manner which allows expression of said enzymatic nucleic acid molecules.
Claim 9
Dependent Claim
14 words
The expression vector of claim 7, wherein said expression vector is a viral vector.
Claim 10
Dependent Claim
14 words
The expression vector of claim 8, wherein said viral vector is a retrovirus vector.
Claim 11
Dependent Claim
17 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is chemically synthesized.
Claim 12
Dependent Claim
18 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic molecule is in a purified form.
Claim 13
Dependent Claim
22 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic RNA molecule is active in the presence of divalent metal ions.
Claim 14
Dependent Claim
15 words
The enzymatic nucleic acid molecule of claim 12, wherein said divalent metal ion is magnesium.
Claim 15
Dependent Claim
17 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic molecule comprises a sugar modification.
Claim 16
Dependent Claim
25 words
The expression vector of claim 7, wherein said nucleic acid sequence encoding said enzymatic RNA molecule is under the control of a mammalian transcription promoter.
Claim 17
Dependent Claim
15 words
The expression vector of claim 15, wherein said mammalian transcription promoter is from a cytomegalovirus.
Claim 18
Dependent Claim
35 words
A method of cleaving RNA encoded by the nef gene comprising the step of contacting said RNA with the enzymatic nucleic acid molecule of claim 1 under conditions suitable for the cleavage of said RNA.
Claim 19
Dependent Claim
22 words
A mammalian cell including the enzymatic nucleic acid molecule of claim 1, wherein the mammalian cell is not part of a mammal.
Claim 20
Dependent Claim
14 words
The mammalian cell of claim 18, wherein said mammalian cell is a human cell.
Claim 21
Dependent Claim
10 words
A mammalian cell including the expression vector of claim 7.
Claim 22
Dependent Claim
14 words
The mammalian cell of claim 20, wherein said mammalian cell is a human cell.
Claim 23
Dependent Claim
19 words
The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule comprises a poly A tail.
References Cited (Backward Citations)
US4987071A
Cited
EP0331939A2
Cited
EP0360257A2
Cited
US5527895A
Cited
US5168053A
Cited
US5144019A
Cited
WO1991003162A1
Cited
US5149796A
Cited
WO1991004319A1
Cited
WO1991004324A1
Cited
WO1991010453A1
Cited
US5278956A
Cited
WO1991015500A1
Cited
WO1991015580A1
Cited
WO1992001806A1
Cited
WO1993005147A1
Cited
WO1993023569A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-10-25 | 2003-04-26 | 2003-10-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-10-25 | 2007-04-26 | 2007-10-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-10-25 | 2011-04-26 | 2011-10-26 | $7700.00 | Window Closed / Lapsed |